GlassScriptPhysician profile
Alicia Ali
NPI 1154926608
$3,364.96
in general payments reported to CMS, 2019-2025
24 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $511 · 2023: $277 · 2024: $763 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.74 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $349.86 | 2024-2025 | Wegovy |
| Gilead Sciences, INC. | $342.26 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.09 | 2024-2025 | Ofev, Jascayd |
| Sumitomo Pharma America, INC. | $240.68 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $231.73 | 2025 | Cresemba |
| Alexion Pharmaceuticals, INC. | $229.65 | 2022-2024 | Ultomiris |
| Inari Medical, INC. | $159.56 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $157.46 | 2022-2025 | Livtencity |
| Teva Pharmaceuticals USA, INC. | $131.58 | 2021 | |
| Intercept Pharmaceuticals, INC. | $121.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $120.40 | 2021 | |
| Amgen INC. | $120.09 | 2021 | |
| Inspire Medical Systems, INC. | $119.56 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $117.12 | 2025 | Fasenra |
| Coloplast Corp | $113.84 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112.75 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.14 | 2025 | Lifevest |
| United Therapeutics Corporation | $87.69 | 2025 | Tyvaso, Steen Solution |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.19 | 2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $43.85 | 2021 | |
| Edwards Lifesciences Corporation | $34.00 | 2024 | Hemosphere |
| Biohaven Pharmaceutical Holding Company LTD. | $28.21 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $24.30 | 2025 | Envarsus |
| Merck Sharp & Dohme LLC | $15.45 | 2025 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.